Comment by Steve Quessy on: Jeffrey Mogil. What is the reason for lack of translation in the pain field?. Pain Research Forum 28 Mar 2011. Available at http://painresearchforum.org/forums/discussion/4561-what-reason-lack-translation-pain-field. Accessed 12 May 2011.
Quessy SN. Study selection criteria and the choices we make. Pain 2011;152(3):471-2; doi:101016/j.pain.2010.11.028
Quessy SN. Where are the new analgesics? An alternative approach to early phase analgesic trials using a multivariable input model with adaptively allocated enrichment. Pain 2010;151(2):247-50; doi:10.1016/j.pain.2010.05.025
Quessy SN. The challenges of translational research for analgesics: The state of knowledge needs upgrading and some uncomfortable deficiencies remain to be urgently addressed. J Pain 2010;11(7):698-700. doi:10.1016/jpain.2010.05.001
Dworkin R, Turk D, Peirce-Sandner S, Baron R, Bellamy N, Burke L, Chappell A, Chartier K, Cleeland C, Costello A, Cowan P, Dimitrova R, Ellenberg S, Farrar J, French J, Gilron I, Hertz S, Jadad A, Jay G, Kalliomaki J, Katz N, Kerns R, Manning D, McDermott M, McGrath P, Naravana A, Porter L, Quessy S, Rappaport B, Rauschkolb C, Reeve B, Rhodes T, Sampaio C, Simpson D, Stauffer J, Stucki G, Tobias J, White R, Witter J. Research design considerations for confirmatory chronic pain clinical trials: IMMPACT recommendations. Pain 2010;140(2):177-193. doi:10.1016/j.pain. 2010.02.018.
Quessy SN. Two-stage enriched enrolment pain trials. A brief reviw of designs and opportunities for broader application. Pain 2010;148(1):8-13. doi 10.1016/j.pain. 2009.10.029
Quessy SN. Comment on: Animal models and the prediction of efficacy in clinical trials of analgesic drugs: A critical appraisal and a call for uniform reporting standards. Pain 2009;142(3):284-5. doi:10.1016/j.pain.2009.01.030
Shackelford S, Rauck R, Quessy SN, Blum D, Hodge RA, Philipson RS. A randomized, double-blind, placebo-controlled trial of a selective COX-2 inhibitor, GW406381 in patients with postherpetic neuralgia. J Pain 2009;10(6):654-660
Varner J, Lomax M, Blum D, Quessy SN. A randomized, controlled, dose-ranging study investigating single doses of GW406381, naproxen sodium or placebo in subjects with acute pain following third molar tooth extraction. Clin J Pain 2009;25(7):577-583
Quessy SN, Rowbothom MC. Placebo response in neuropathic pain. Pain 2008;138(3):479-483. doi:10.1016/j.pain.2008.06.024
DC Turk, RH Dworkin, N Bellamy, LB Burke, JM Chandler, CS Cleeland, P Cowan, R Dimitrova, JT Farrar, S Hertz, JF Heyse, S Iyengar, AR Jadad, GW Jay, JA Jermano, NP Katz, DC Manning, S Martin, MB Max, M McDermott, P McGrath, HJ McQuay, LA. Moyé, III, G Niebler, T Permutt, S Quessy, RA Rappaport, DA Revicki, M Rothman, JW Stauffer, O Svensson, RE White, and J Witter. Analyzing multiple endpoints in clinical trials of pain treatments: IMMPACT recommendations. Pain 2008;139(3):485-93. doi:10.1016/j.pain.2008.06.025
Boswell DJ, Ostergaard K, Philipson RS, Hodge RA, Blum D, Brown JC, Quessy SN. Evaluation of GW406381 for treatment of osteoarthritis of the knee: two randomized, controlled studies. Medscape J Med 2008;10(11):259
RH Dworkin, DC Turk, KW Wyrwich, DBeaton, CS Cleeland, JT Farrar, JA Haythornthwaite, MP Jensen, RD Kerns, DN Ader, N Brandenburg, LB Burke, D Cella, J Chandler, P Cowan, R Dimitrova, R Dionne, S Hertz, AR Jadad, NP Katz, H Kehlet, LD Kramer, DC Manning, C McCormick, MP McDermott, HJ McQuay, S Patel, L Porter, S Quessy, RA Rappaport, C Rauschkolb, DA Revicki, M Rothman, KE Schmader, BR Stacey, JW Stauffer, T von Stein, RE White, J Witter, S Zavisic. Interpreting the Clinical Importance of Treatment Outcomes in Chronic Pain Clinical Trials: IMMPACT Recommendations. J Pain 2008;9(2):105-121
M Silver, D Blum, J Grainger, A Hammer, S Quessy. Double-blind, placebo-controlled trial of lamotrigine with other medications for neuropathic pain. J Pain and Symptom Management 2007;34(4):446-454
A Vinik, M Tuchman, B Safirstein, C Corder, L Kirby, K Wilks, S Quessy, D Blum, J Grainger, J White, M Silver. Lamotrigine for treatment of pain associated with diabetic neuropathy: results of two randomized, double-blind, placebo-controlled studies. Pain 2007;128:169-179
DC Turk, RH Dworkin, LB Burke, R Gershon, M Rothman, J Scott, RR Allen, JH Atkinson, J Chandler, C Cleeland, P Cowan, R Dimitrova, R Dionne, JT Farrar, JA Haythornthwaite, S Hertz, AR Jadad, MP Jensen, D Kellstein, RD Kerns, DC Manning, S Martin, MB Max, MP McDermott, P McGrath, DE Moulin, T Nurmikko, S Quessy, S Raja, RA Rappaport, C Rauschkolb, JP Robinson, M Royal, L Simon, JW Stauffer, G Stucki, J Tollett, T von Stein, MS Wallace, J Wernicke, RE White, AC Williams, J Witter, and KW Wyrwich. Developing patient-reported outcome measures for pain clinical trials: IMMPACT recommendations. Pain 2006;125:208-215
RH Dworkin, DC Turk, JT Farrar, J Haythornthwaite, MP Jensen, NP Katz, RD Kerns, G Stucki, RR Allen, N Bellamy, DB Carr, J Chandler, P Cowen, R Dionne, BS Galer, S Hertz, A Jadad, LD Kramer, DC Manning, S Martin, CG McCormick, M McDermott, P McGrath, S Quessy, RA Rapport, W Robbins, JP Robinson, M Rothman, MA. Royal, L Simon, JW Stauffer, W Stein, J Tollett, J Wernicke, J Witter. Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. Pain 2005;113:9-19
M.S. Wallace, S. Quessy, G. Schulteis. Lack of effect of two oral sodium channel antagonists, lamotrigine and 45030W92, on intradermal capsaicin-induced hyperalgesia model. Pharmacol. Biochem. Behav. 2004;78(2):349-355
DC Turk, RH Dworkin, RR Allen, N Bellamy, N Brandenburg, DB Carr, C Cleeland, R Dionne, JT Farrar, BS Galer, DJ Hewitt, A Jadad, NP Katz, LD Kramer, DC Manning, CG McCormick, M McDermott, P McGrath, S Quessy, RA Rapport, JP Robinson, MA. Royal, L Simon, JW Stauffer, W Stein, J Tollett, J Witter. Core outcome domains for chronic pain clinical trials: IMMPACT recommendations. Pain 2003;106:337-345
M.S. Wallace, M.C. Rowbothom, N. Katz, R.H. Dworkin, R.M. Dotson, B.S. Galer, R.L. Rauck, M.M. Backonja, S.N. Quessy, P.D. Meisner. A randomized, double-blind, placebo-controlled trial of a glycine antagonist in neuropathic pain. Neurology 59:1694-1699; 2002
M.S.Wallace, M.C.Rowbothom, G.M. Bennett, T.S.Jensen, R. Pladna, and S.Quessy, A multicenter, double-blind, randomized, placebo-controlled crossover evaluation of a short course 4030W92 in patients with chronic neuropathic pain, J Pain 3(3):227-233; 2002
L.S. Bluestein, L.W. Stinson, R.O. Lennon, S.N. Quessy, and R.M. Wilson: Evaluation of cisatracurium, a new neuromuscular blocking agent, for endotracheal intubation. Can J. Anesthesiology, 49 (9): 925-931; 1996.
M.R. Belmont, C.A. Lien, S. Quessy, M.M. Abou-Donia, A. Abalos, L. Eppich, J.J. Savarese: The clinical neuromuscular pharmacology of 51W89. Anesthesiology 82: 1139-1145; 1995.
C.A. Lien, M.R. Belmont, A. Abalos, L. Eppich, S. Quessy, M.M. Abou-Donia, J.J. Savarese: Cardiovascular effects and histamine releasing properties of 51W89 in patients receiving nitrous oxide/opioid/barbiturate anesthesia. Anesthesiology 82: 1131-1138; 1995.
J.S. Larsen, M. Hahn, J.W. Kochevar, R.J. Morris, H.B. Kaiser, S.C. Weisberg, P.C. Halverson, and S.N. Quessy: Administration errors with a conventional metered dose inhaler versus a novel breath actuated inhaler. Annals of Allergy 71: 103-106, 1993.
S.N. Quessy, R.J. Morris, J.S. Larsen, H.B. Kaiser, S.C. Weisberg and P.C. Halverson: Sensitivity of FEV1 response following one and two inhalations of albuterol. J. Asthma 28:323-328, 1991
N. Barr, S.F. Dyke and S.N. Quessy: Palladium assisted organic reactions IV. A new isoquinoline synthesis. Organomet Chem 253: 391-397; 1983
S.F. Dyke and S.N. Quessy: Regioselectivity in the cyclopalladation of arylidenemethylamines (schiff's bases). Transition Metal Chem 7: 233-234; 1982
V.G Baddeley, S.N. Quessy and L.R. Williams: C-13 NMR studies of 4-hydroxytetrahydroisoquinolinium salts. Aust J Chem 33: 447-450; 1980
S.N. Quessy and L.R. Williams: Synthesis and biological evaluation of 4-hydroxytetrahydroisoquinoline derivatives. Aust J Chem 32: 1317-1327; 1979
P.W. Freeman, S.N. Quessy and L.R. Williams: Synthesis of dihydroxyoxazines from a modified Bischler-Napieralski reaction. Synthetic Commun 9: 631-637; 1979
S.N. Quessy, L.R. Williams and V.G. Baddeley: Ring cyclised products from the Delepine reaction. J Chem Soc Perkin Trans I 512-516; 1979
S.N. Quessy, L.R. Williams and V.G. Baddeley: A ring cyclised product from the Delepine reaction Synthetic Commun 8: 45-51; 1978
L.G. Letts, P.A. Eassen, D.M. Temple, B.V. Lap, C.H. Lim, A.J. Orr, S.J. Pasaribu, S.N. Quessy and L.R. Williams: The beta adrenergic activity of some monosubstituted phenethanolamines. Arch Int Pharmacodyn Ther 230: 42-52; 1977
L. Kirby, C. Corder, K. Wilks, D. Blum, J. Grainger, M. Silver, S. Quessy, J White. Tolerability of lamotrigine in painful diabetic neuropathy: results from two large double-blind trials. J. Pain 2005;6(3) Suppl 1:S34 (abstr #703)
P. Meisner, J. Appleby, D. Blum, R. Dixon, A. Nelson, S. Quessy, S. Shaikh, J. White, P. Williams. A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Tolerability of a 14 Day Treatment Course of GW493838 50mg Compared to Placebo in Subjects with Peripheral Neuropathic Pain (GlaxoSmithKline Study A1A20004). 11th World congress of Pain, 2005 Abstr p637 (#243).
M. Tuchman, D. Blum, M. Silver, J. Grainger, J. White, S. Quessy. Long-term Tolerability of Lamotrigine in Patients with Painful Diabetic Neuropathy. 11th World Congress of Pain, 2005 Abstr p604 (#210).
C. McClung, S. Quessy, S. Julious, A. Segreti, D. Blum. Placebo response rates and geographic location in COX-2 inhibitor trials of rheumatoid arthritis (RA) and osteoarthritis (OA): a meta analysis. Arthritis and Rheumatism 2004; 50 (9) Suppl. (abstract #1453)
E.G. Pavlin, A.P. Forrest, M. Howard, S. Quessy, C. McClung: Prior administration of succinylcholine (SCh) does not affect the duration of NIMBEX (51W89) neuromuscular blockade. Anesthesia and Analgesia 80: S374; 1995.
C.A. Lein, R. S. Matteo, E. Ornstein, S. Quessy, J.J. Savarese: Neostigmine antagonism of doxacurium or pancuronium blockade under isoflurane. Anesthesiology 77:A960, 1992.
D.G. Tinkleman, S.N. Quessy and B.P. Ekholm: Analysis of cardiovascular data on pirbuterol, a relatively selective beta-2 agonist. Annals of Allergy 64(1): 93, 1990.
L.R. Williams, S. Pasaribu, B. Lapp, A. Orr, S. Quessy, D. Sutherland, and D.M. Temple: Structure activity studies of mono substituted phenethanolamines Proc Aust Physiol Pharmacol Soc 5: 253, 1974.
S. Quessy Issues relating to the clinical development process of new analgesics: In J Mogil Ed. Pain 2010 - An updated review: refresher course syllabus. IASP Press, 2010. p437-445
S. Quessy Overview of the drug development process and regulatory approval for new drugs: In J Mogil Ed. Pain 2010 - An updated review: refresher course syllabus. IASP Press, 2010. p409-414
S.F. Dyke and S.N. Quessy: Erythrina Alkaloids In R.G.A. Rodrigo ed. The Alkaloids Vol 18. Academic Press, 1981. p 1-99
Clinical issues in analgesic drug development. Refresher course on Preclinical and Clinical Challenges in Drug Development. (13th World Congress of Pain – Montreal Canada, August 29 2010)
The role of placebo response in neuropathic pain clinical trials. (At 9th International Conference on Neuropathic pain – Snowbird, Utah, November 2007)
An industry view of mechanism-based treatment (Dinner Workshop on How close is mechanism-based treatment? At 7th International Conference on Neuropathic pain – Bermuda, November 2004)
S.N. Quessy, G.D. Rudd, M.F. Winnem: Composition for treating neuropathic pain. Application no 10/115,548 (2002)
R.K. Schultz and S.N. Quessy: The use of soluble fluorosurfactants for the preparation of metered-dose aerosol formulations. USP 5118494 (June 1992); EP 526481 (Feb 1993)